Matthew W. Strobeck - 29 May 2023 Form 4 Insider Report for Accelerate Diagnostics, Inc (AXDX)

Reporting relationship: Director
Issuer ticker: AXDX
Reported as of: 29 May 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Jun 2023, 18:25:27 UTC
Prior SEC filing: 25 May 2023
Next SEC filing: 08 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ David Patience, attorney-in-fact

Key filing fact

Matthew W. Strobeck filed Form 4 for Accelerate Diagnostics, Inc (AXDX) on 01 Jun 2023.

Key facts

This page summarizes Matthew W. Strobeck's Form 4 filing for Accelerate Diagnostics, Inc (AXDX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 01 Jun 2023, 18:25.

Change

Previous filing in this sequence was filed on 25 May 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AXDX transaction Derivative

Employee Restricted Stock Units

Award

Transaction value: $0
Shares: +78,947
Change %
Price: $0.000000
Shares after: 78,947
Date: 29 May 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 78,947
Exercise price
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

Footnote F2

On May 29, 2023, the reporting person was granted RSUs. All of the RSUs shall vest on the first-year anniversary of the Date of Grant (the "Vesting Date"), unless Grantee leaves in good standing before 12 months, in which case they will vest pro-rata based on months served. Pursuant to the issuer's Director Equity Deferral Program, the reporting person has elected to defer receipt of the shares of common stock upon vesting of the restricted stock units to such time that is within 30 days following his departure from the issuer's board of directors.

Footnote F3

Not applicable.